Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

Key Inclusion Criteria: * Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures. * Adult males and non-pregnant, non-lactating females. * Documented evidence of chronic HBV infection. * Hepatitis e antigen (HBeAg)-negative, chronic hepatitis B with all of the following: * HBeAg-negative and hepatitis B e antibody (HBeAb) positive at screening. * Screening HBV DNA ≥ 2 x 10\^4 IU/mL. * Screening serum alanine aminotransferase (ALT) level \> 60 U/L (males) or \> 38 U/L (females) and ≤ 10 x the upper limit of the normal range (ULN). * Treatment-naive participants (defined as \< 12 weeks of oral antiviral treatment with any nucleoside or nucleotide analogue), OR treatment-experienced participants (defined as participants meeting all entry criteria \[including HBV DNA and serum ALT criteria\] and with ≥ 12 weeks of previous treatment with any nucleoside or nucleotide analogue). * Previous treatment with interferon (pegylated or non pegylated) must have ended at least 6 months prior to Baseline. * Adequate renal function. * Normal electrocardiogram (ECG). Key Exclusion Criteria: * Females who are breastfeeding. * Males and females of reproductive potential who are unwilling to use an "effective", protocol-specified method(s) of contraception during the study. * Co-infection with hepatitis C virus, human immunodeficiency virus (HIV), or hepatitis D virus. * Evidence of hepatocellular carcinoma. * Any history of, or current evidence of, clinical hepatic decompensation. * Abnormal hematological and biochemical parameters, including aspartate aminotransferase (AST) \> 10 x ULN * Received solid organ or bone marrow transplant. * History of malignancy within the past 5 years, with the exception of specific cancers that are cured by surgical resection; individuals under evaluation for possible malignancy are not eligible. * Currently receiving therapy with immunomodulators (eg, corticosteroids), investigational agents, nephrotoxic agents, or agents capable of modifying renal excretion. * Individuals receiving ongoing therapy with drugs not to be used with tenofovir alafenamide or tenofovir disoproxil fumarate or individuals with a known hypersensitivity to study drugs, metabolites, or formulation excipients. * Current alcohol or substance abuse judged by the investigator to potentially interfere with participant compliance. * Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with dosing requirements. Note: Other protocol defined Inclusion/Exclusion criteria may apply.